BRAF v600e
Page rank: 5
BRAF v600e- clarientinc.com
The BRAF (V600E) mutation analysis is predictive for anti-EGFR therapies (i.e., cetuximab and panitumumab). BRAF mutations account for approximately 12-15% of colorectal cancer patients.
Keywords:
No review for this site yet
You need to login to post review